Ducobu J
Service de Médecine Interne, C.H.U. de Tivoli, La Louvière.
Rev Med Brux. 1998 Sep;19(4):A379-85.
Diabetes mellitus is a still growing disease. New diagnostic criteria lowered the cut off value to 126 mg/dl, in order to detect more rapidly diabetes and its complications. The treatment of diabetes 2 by the classic oral antidiabetic drugs (sulfamides and biguanides) is completed by intestinal glycosidases inhibitors and thiazolidendiones. These last drugs seem very attractive because they decrease insulin resistance in obese, diabetics. Their hepatic side effects must be however under control. Better knowledge of non lipidic effects of statins on the arterial wall and the discovery of the action of fibrates on PPAR (Peroxisome Proliferator Activated Receptors) improved strongly the therapeutic management of hyperlipidemias. Recent intervention studies have demonstrated the necessity to treat vigorously dysipidemias.
糖尿病是一种仍在增加的疾病。新的诊断标准将临界值降至126毫克/分升，以便更快速地检测出糖尿病及其并发症。经典口服降糖药（磺酰胺类和双胍类）对2型糖尿病的治疗，通过肠道糖苷酶抑制剂和噻唑烷二酮类药物得以完善。这些最新的药物似乎很有吸引力，因为它们可降低肥胖糖尿病患者的胰岛素抵抗。然而，其肝脏副作用必须得到控制。对他汀类药物在动脉壁上的非脂质效应的更深入了解，以及对贝特类药物作用于过氧化物酶体增殖物激活受体（PPAR）的发现，极大地改善了高脂血症的治疗管理。最近的干预研究表明，必须积极治疗血脂异常。
